Investigators Update

Document Sample
Investigators Update Powered By Docstoc
					                          Investigators’ Update                                                                  March 2009
                                                                                                                Volume 1 Issue 1

                          Locate Georgia cancer trials:
                          Find Georgia oncologists:
                                                                                                                Event Calendar:
Early Stage Breast Cancer Study                        Georgia CORE GOG Consortium
in Interim Analysis (EU 822-03)                        Membership Performance                                   4/15/09- Breast Cancer
                                                                                                                Working Group
Ruth M. O’Regan, MD, Principal Investigator            Georgia CORE’s Consortium has received                   Meeting 6:30pm
and Amelia Zelnak, Medical Director, have              provisional membership status from the
announced that their randomized phase II trial         Gynecologic Oncology Group. According to                 Sponsored by
of preoperative docetaxel and capecitabine             Donald G. Gallup, MD, Principal Investigator, this       Monogram Biosciences
given sequentially or concurrently for Her2            unique statewide Consortium offers Georgia
negative breast cancers is in interim analysis and     investigators the opportunity to open GOG trials         Featured Presentation
temporarily closed to accrual. The study is            provided that the Consortium accrues at least 150        Measuring the Target
sponsored by Georgia CORE and funded by                membership points in specific categories during the      – A Functional
Sanofi-Aventis.                                        year.                                                    Proteomic Approach to
                                                                                                                Personalized Medicine”
51 patients (64% of a projected 80 patients)           Currently active members of the Georgia CORE
from 7 sites in the CORE Research Network              GOG Consortium, Mercer/Memorial University               Panel Discussion
have enrolled in the study. Participating sites        and the Medical College of Georgia, are on target to     Her2 Testing and
include: Amos Cancer Center/Columbus                   accrue half of the points by mid-year, ensuring that     Management of Small
Regional, Augusta Oncology Associates,                 provisional membership status is maintained. The         Her2+ Cancers
Central Georgia Cancer Care, Dekalb                    sites are accruing a greater percentage of patients to
Medical/Georgia Cancer Specialists, Emory              high priority GOG studies. Mitchell Z. Berger, MD        RSVP to Shaunta
Winship Cancer Institute, Georgia Cancer               has recently announced plans to open GOG studies         Wright at
Center for Excellence/Grady Health System,             at the Georgia Cancer Center for Excellence at 
Wellstar Health System/Northeast Georgia                                                                        or 404-584-8697
                                                       Grady Health System.
Oncology Centers.

Preliminary results of the study were reported          Figure 1
at San Antonio Breast Cancer Symposium in
December of 2008. The report was the first of
its kind co-authored by academic and
community oncologists and clinical research
professionals active in the Georgia CORE
network including Drs. Gabram, Hermann,
O’Regan, Schnell, Srinivasiah and Zelnak. 49%
of the patients enrolled in the study at the time
of the report were African American.
                                                                                                                  Georgia CORE™
Her2 Over Expressing Early                                                                                        50 Hurt Plaza
                                                                                                                  Suite 704
Stage Breast Cancer Study                                                                                         Atlanta, GA 30303
Actively Accruing                                                                                                 404-523-8735
ABX018, the neoadjuvant trial of Trastuzumab in                                                         
combination with dose-dense ABI007 (Abraxane)
followed by Vinorelbine sponsored by Georgia CORE                  For study information
                                                                   contact:                                       Georgia CORE is
and funded by Abraxis, is actively accruing patients.                                                             generously supported
                                                                   Diane Hicklin-Coleman, MPA
                                                                   Research Director                              by the Georgia Cancer
Currently 14 (28% of a projected 50 patients) have                                                                Coalition, Emory
been enrolled from the following CORE Research                     770-313-4055
                                                                   404-588-4082                                   Winship Cancer
Network sites: Dekalb Medical/Georgia Cancer                                                                      Institute and Georgia
Specialists, Emory/Winship Cancer Institute, Georgia     
                                                                                                                  oncologists dedicated
Cancer Center for Excellence/Grady Health System,                                                                 to today’s cancer care
Northeast Georgia Cancer Care, Piedmont                                                                           and tomorrow’s
Hospital/Peachtree Hematology Oncology                                                                            cancer cure.